Research ExplorerPublicationsManagement of adults and children receiving CAR T-cell thera...

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Standard

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). / Hayden, P J; Roddie, C; Bader, P; Basak, G W; Bonig, H; Bonini, C; Chabannon, C; Ciceri, F; Corbacioglu, S; Ellard, R; Sanchez-Guijo, F; Jäger, U; Hildebrandt, M; Hudecek, M; Kersten, M J; Köhl, U; Kuball, J; Mielke, S; Mohty, M; Murray, J; Nagler, A; Rees, J; Rioufol, C; Saccardi, R; Snowden, J A; Styczynski, J; Subklewe, M; Thieblemont, C; Topp, M; Ispizua, Á U; Chen, D; Vrhovac, R; Gribben, J G; Kröger, N; Einsele, H; Yakoub-Agha, I.

In: ANN ONCOL, Vol. 33, No. 3, 03.2022, p. 259-275.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hayden, PJ, Roddie, C, Bader, P, Basak, GW, Bonig, H, Bonini, C, Chabannon, C, Ciceri, F, Corbacioglu, S, Ellard, R, Sanchez-Guijo, F, Jäger, U, Hildebrandt, M, Hudecek, M, Kersten, MJ, Köhl, U, Kuball, J, Mielke, S, Mohty, M, Murray, J, Nagler, A, Rees, J, Rioufol, C, Saccardi, R, Snowden, JA, Styczynski, J, Subklewe, M, Thieblemont, C, Topp, M, Ispizua, ÁU, Chen, D, Vrhovac, R, Gribben, JG, Kröger, N, Einsele, H & Yakoub-Agha, I 2022, 'Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)', ANN ONCOL, vol. 33, no. 3, pp. 259-275. https://doi.org/10.1016/j.annonc.2021.12.003

APA

Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., Sanchez-Guijo, F., Jäger, U., Hildebrandt, M., Hudecek, M., Kersten, M. J., Köhl, U., Kuball, J., Mielke, S., Mohty, M., ... Yakoub-Agha, I. (2022). Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). ANN ONCOL, 33(3), 259-275. https://doi.org/10.1016/j.annonc.2021.12.003

Vancouver

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). ANN ONCOL. 2022 Mar;33(3):259-275. https://doi.org/10.1016/j.annonc.2021.12.003

Bibtex

@article{873206e6148c4d1f9f7ba5d54e2a4faa,
title = "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)",
abstract = "BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future.DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field.RESULTS: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues.CONCLUSIONS: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.",
author = "Hayden, {P J} and C Roddie and P Bader and Basak, {G W} and H Bonig and C Bonini and C Chabannon and F Ciceri and S Corbacioglu and R Ellard and F Sanchez-Guijo and U J{\"a}ger and M Hildebrandt and M Hudecek and Kersten, {M J} and U K{\"o}hl and J Kuball and S Mielke and M Mohty and J Murray and A Nagler and J Rees and C Rioufol and R Saccardi and Snowden, {J A} and J Styczynski and M Subklewe and C Thieblemont and M Topp and Ispizua, {{\'A} U} and D Chen and R Vrhovac and Gribben, {J G} and N Kr{\"o}ger and H Einsele and I Yakoub-Agha",
note = "Copyright {\textcopyright} 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2022",
month = mar,
doi = "10.1016/j.annonc.2021.12.003",
language = "English",
volume = "33",
pages = "259--275",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

AU - Hayden, P J

AU - Roddie, C

AU - Bader, P

AU - Basak, G W

AU - Bonig, H

AU - Bonini, C

AU - Chabannon, C

AU - Ciceri, F

AU - Corbacioglu, S

AU - Ellard, R

AU - Sanchez-Guijo, F

AU - Jäger, U

AU - Hildebrandt, M

AU - Hudecek, M

AU - Kersten, M J

AU - Köhl, U

AU - Kuball, J

AU - Mielke, S

AU - Mohty, M

AU - Murray, J

AU - Nagler, A

AU - Rees, J

AU - Rioufol, C

AU - Saccardi, R

AU - Snowden, J A

AU - Styczynski, J

AU - Subklewe, M

AU - Thieblemont, C

AU - Topp, M

AU - Ispizua, Á U

AU - Chen, D

AU - Vrhovac, R

AU - Gribben, J G

AU - Kröger, N

AU - Einsele, H

AU - Yakoub-Agha, I

N1 - Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2022/3

Y1 - 2022/3

N2 - BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future.DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field.RESULTS: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues.CONCLUSIONS: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.

AB - BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future.DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field.RESULTS: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues.CONCLUSIONS: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.

U2 - 10.1016/j.annonc.2021.12.003

DO - 10.1016/j.annonc.2021.12.003

M3 - SCORING: Journal article

C2 - 34923107

VL - 33

SP - 259

EP - 275

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 3

ER -